Co-delivery doxorubicin and silybin for anti-hepatoma via enhanced oral hepatic-targeted efficiency

BACKGROUND: To establish the combination of doxorubicin (DOX) and silybin (SLB) in oral hepatic-targeting liposomes with the goal of reducing cardiotoxic side effects and improve oral hepatoma treatment. METHODS: Distearoylphosphatidylethanolamine–polyethylene glycol–cholic acid-modified liposomes (...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Ying, Yang, Dandan, Wang, Yian, Li, Zhan, Zhu, Chunyan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314320/
https://www.ncbi.nlm.nih.gov/pubmed/30643408
http://dx.doi.org/10.2147/IJN.S187888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314320/
https://www.ncbi.nlm.nih.gov/pubmed/30643408
http://dx.doi.org/10.2147/IJN.S187888

Ejemplares similares